{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T20:54:20Z","timestamp":1782680060885,"version":"3.54.5"},"reference-count":26,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1188\/19.cjon.e73-e80","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T10:15:44Z","timestamp":1563531344000},"page":"E73-E80","source":"Crossref","is-referenced-by-count":3,"title":["Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab"],"prefix":"10.1188","volume":"23","author":[{"given":"Marianne","family":"Tawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"\ufeffBagherani, N., & Smoller, B.R. (2016). An overview of cutaneous T cell lymphomas. F1000Research, 5, 1882. https:\/\/doi.org\/10.12688\/f1000research.8829.1","DOI":"10.12688\/f1000research.8829.1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bradford, P.T., Devesa, S.S., Anderson, W.F., & Toro, J.R. (2009). Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood, 113, 5064\u20135073. https:\/\/doi.org\/10.1182\/blood-2008-10-184168","DOI":"10.1182\/blood-2008-10-184168"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Chung, C.G., & Poligone, B. (2015). Cutaneous T cell lymphoma: An update on pathogenesis and systemic therapy. Current Hematologic Malignancy Reports, 10, 468\u2013476. https:\/\/doi.org\/10.1007\/s11899-015-0293-y","DOI":"10.1007\/s11899-015-0293-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Demierre, M.F., Gan, S., Jones, J., & Miller, D.R. (2006). Significant impact of cutaneous T-cell lymphoma on patients\u2019 quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer, 107, 2504\u20132511. https:\/\/doi.org\/10.1002\/cncr.22252","DOI":"10.1002\/cncr.22252"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Duvic, M., Pinter-Brown, L.C., Foss, F.M., Sokol, L., Jorgensen, J.L., Challagundla, P., . . . Kim, Y.H. (2015). Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood, 125, 1883\u20131889. https:\/\/doi.org\/10.1182\/blood-2014-09-600924","DOI":"10.1182\/blood-2014-09-600924"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Ferenczi, K., Fuhlbrigge, R.C., Pinkus, J., Pinkus, G.S., & Kupper, T.S. (2002). Increased CCR4 expression in cutaneous T cell lymphoma. Journal of Investigative Dermatology, 119, 1405\u20131410. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.19610.x","DOI":"10.1046\/j.1523-1747.2002.19610.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Foss, F.M., & Girardi, M. (2017). Mycosis fungoides and Sezary syndrome. Hematology\/Oncology Clinics of North America, 31, 297\u2013315. https:\/\/doi.org\/10.1016\/j.hoc.2016.11.008","DOI":"10.1016\/j.hoc.2016.11.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hwang, S.T., Janik, J.E., Jaffe, E.S., & Wilson, W.H. (2008). Mycosis fungoides and S\u00e9zary syndrome. Lancet, 371, 945\u2013957. https:\/\/doi.org\/10.1016\/s0140-6736(08)60420-1","DOI":"10.1016\/S0140-6736(08)60420-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Ishida, T., Inagaki, H., Utsunomiya, A., Takatsuka, Y., Komatsu, H., Iida, S., . . . Ueda, R. (2004). CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clinical Cancer Research, 10, 5494\u20135500. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0371","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., . . . Ueda, R. (2012). Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. Journal of Clinical Oncology, 30, 837\u2013842. https:\/\/doi.org\/10.1200\/JCO.2011.37.3472","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"11","unstructured":"Ishida, T., Utsunomiya, A., Iida, S., Inagaki, H., Takatsuka, Y., Kusumoto, S., . . . Ueda, R. (2003). Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: Its close association with skin involvement and unfavorable outcome. Clinical Cancer Research, 9, 3625\u20133634."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Ishii, T., Ishida, T., Utsunomiya, A., Inagaki, A., Yano, H., Komatsu, H., . . . Ueda, R. (2010). Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clinical Cancer Research, 16, 1520\u20131531. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2697","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kim, Y.H., Bagot, M., Pinter-Brown, L., Rook, A.H., Porcu, P., Horwitz, S.M., . . . Duvic, M. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial. Lancet Oncology, 19, 1192\u20131204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Korgavkar, K., Xiong, M., & Weinstock, M. (2013). Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatology, 149, 1295\u20131299. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5526","DOI":"10.1001\/jamadermatol.2013.5526"},{"key":"15","unstructured":"Kyowa Kirin. (2018). Poteligeo\u00ae (mogamulizumab-kpkc) [Package insert]. Retrieved from https:\/\/www.poteligeohcp.com\/assets\/files\/full-prescribing-information.pdf"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Molloy, K., Jonak, C., Woei-A-Jin, F.J.S.H., Guenova, E., Busschots, A.M., Bervoets, A., . . . Scarisbrick, J. (2019). Characteristics associated with significantly worse quality of life in mycosis fungoides\/S\u00e9zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. British Journal of Dermatology. Advance Online Publication. https:\/\/doi.org\/10.1111\/bjd.18089","DOI":"10.1111\/bjd.18089"},{"key":"17","unstructured":"National Comprehensive Cancer Network. (2019). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Primary cutaneous lymphomas [v2.2019]. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., . . . Ueda, R. (2014). Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Journal of Clinical Oncology, 32, 1157\u20131163. https:\/\/doi.org\/10.1200\/JCO.2013.52.0924","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ollila, T.A., Sahin, I., & Olszewski, A.J. (2019). Mogamulizumab: A new tool for management of cutaneous T-cell lymphoma. OncoTargets and Therapy, 12, 1085\u20131094. https:\/\/doi.org\/10.2147\/OTT.S165615","DOI":"10.2147\/OTT.S165615"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Olsen, E.A., Whittaker, S., Kim, Y.H., Duvic, M., Prince, H.M., Lessin, S.R., . . . Vonderheid, E.C. (2011). Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 29, 2598\u20132607. https:\/\/doi.org\/10.1200\/jco.2010.32.0630","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Scarisbrick, JJ., Prince, H.M., Vermeer, M.H., Quaglino, P., Horwitz, S., Porcu, P., . . . Kim, Y.H. (2015). Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. Journal of Clinical Oncology, 33, 3766\u20133773. https:\/\/doi.org\/10.1200\/jco.2015.61.7142","DOI":"10.1200\/JCO.2015.61.7142"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Subramaniam, J.M., Whiteside, G., McKeage, K., & Croxtall, J.C. (2012). Mogamulizumab: First global approval. Drugs, 72, 1293\u20131298. https:\/\/doi.org\/10.2165\/11631090-000000000-00000","DOI":"10.2165\/11631090-000000000-00000"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Teras, L.R., DeSantis, C.E., Cerhan, J.R., Morton, L.M., Jemal, A., & Flowers, C.R. (2016). 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA: A Cancer Journal for Clinicians, 66, 443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","DOI":"10.3322\/caac.21357"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Wilcox, R.A. (2016). Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 91, 151\u2013165. https:\/\/doi.org\/10.1002\/ajh.24233","DOI":"10.1002\/ajh.24233"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Willemze, R., Hodak, E., Zinzani, P.L., Specht, L., & Ladetto, M. (2013). Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24(Suppl. 6), vi149-vi154. https:\/\/doi.org\/10.1093\/annonc\/mdt242","DOI":"10.1093\/annonc\/mdt242"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Yoshie, O., Fujisawa, R., Nakayama, T., Harasawa, H., Tago, H., Izawa, D., . . . Yamada, Y. (2002). Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood, 99, 1505\u20131511.","DOI":"10.1182\/blood.V99.5.1505"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/23\/4\/cutaneous-t-cell-lymphoma-optimizing-care-patients-receiving-anti-ccr4-monoclonal-antibody","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:45Z","timestamp":1763754645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/23\/4\/cutaneous-t-cell-lymphoma-optimizing-care-patients-receiving-anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1188\/19.cjon.e73-e80","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}